Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 109.97$. Average daily volumn in 3 months 1.48M. Market cap 254.03B



Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 112.12$. Total volume : 1.43M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price
112.12$
Change
3.69
Volume
1.43M

Previous Close108.43
Open111.81
Day Range110.58-112.20
Bid111.88 x 800
Ask112.50 x 800
Volume1.43M
Average Volume1.48M
Market Cap254.03B
Beta0.24
52 Week Range82.82-122.16
Trailing P/E36.95
Foward P/E28.38
Dividend (Yield %)1.49%
Ex-Dividend Date2022-03-25



Financial Details


According to Novo Nordisk A/S's financial reports the company's revenue in 2021 were 140.8B an increase( +11.11%) over the years 2020 revenue that were of 126.95B. In 2021 the company's total earnings were 47.76B while total earnings in 2020 were 42.14B( +11.9%).


Loading ...



Organization

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Market Cap:
254.03B
Revenue:
140.8B
Total Assets:
194.51B
Total Cash:
10.72B



News about "Novo Nordisk A/S"

private-trust-co-na-has-336000-stock-position-in-novo-nordisk-as-nysenvo-image

Private Trust Co. NA Has $336,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 2 days ago

Private Trust Co. NA raised its position in shares of Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 34.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,022 ...See details»


novo-nordisk-as-share-repurchase-programme-image

Novo Nordisk A/S โ€“ Share repurchase programme

Source from : Yahoo - 6 days ago

On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»


first-hawaiian-bank-acquires-366-shares-of-novo-nordisk-as-nysenvo-image

First Hawaiian Bank Acquires 366 Shares of Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 2 days ago

First Hawaiian Bank increased its position in Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) by 18.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 2,368 shares of the ...See details»


is-novo-nordisk-nvo-a-smart-long-term-investment-image

Is Novo Nordisk (NVO) a Smart Long-Term Investment?

Source from : Insider Monkey - 11 days ago

Baron Funds, an asset management firm, published its โ€œBaron Health Care Fundโ€ first quarter 2022 investor letter โ€“ a copy of which can be downloaded here.See details»


Novo Nordisk A/S:

Source from : Middle East North Africa Financial Network - 19 days ago

Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com , Facebook , Twitter ...See details»


Novo Nordisk A/S (NYSE:NVO) Short Interest Down 29.0% in May

Source from : ETF Daily News - 11 days ago

Novo Nordisk A/S (NYSE:NVO โ€“ Get Rating) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 1,710,000 shares, a drop of 29.0% from ...See details»


Novo Nordisk A/S ADR - Stock Dividends 0TDD

Source from : Morningstar%2c Inc. - 12 days ago

We provide a platform for our authors to report on investments fairly, accurately, and from the investorโ€™s point of view. We also respect individual opinionsโ€“โ€“they represent the unvarnished ...See details»


echosens-and-novo-nordisk-announce-partnership-to-increase-awareness-and-advance-early-diagnosis-of-nash-image

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

Source from : YAHOO!Finance - 4 days ago

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of ...See details»


Novo Nordisk A/S: Major shareholder announcement

Source from : Finanznachrichten - 18 days ago

Novo Nordisk's B shares are listed on Nasdaq Copenhagen, Facebook, Twitter, LinkedIn and YouTube. Further information Company announcement No 50 / 2022 Annex:Full chain of controlled undertakings ...See details»


Johnson & Johnson Or Novo Nordisk: Which Is The Best Big Pharma Near Cap-Gainer

Source from : Seeking Alpha - 10 days ago

In this article, I discuss about Johnson & Johnson and Novo Nordisk. Read more to know among JNJ and NVO stocks, which one is attractive.See details»


Will investors benefit from quality and momentum at Novo Nordisk A/S?

Source from : Yahoo Finance - 3 days ago

The Novo Nordisk A/S (CPH:NOVO B) share price is currently trading at DKK761.9. But to predict what the price will look like in the next 12 months and beyond, ...See details»


3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock

Source from : YAHOO!Finance - 8 days ago

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth ...See details»


Novo Nordisk, Echosens team up to advance early diagnosis, awareness for liver disease

Source from : Seeking Alpha - 3 days ago

Denmark's Novo Nordisk (NVO) andย France-based technology company Echosens are collaboratingย to advance early diagnosis of non-alcoholic steatohepatitis ((NASH)) and increase ...See details»


novo-nordisk-and-echosens-collaborate-to-advance-early-diagnosis-of-non-alcoholic-steatohepatitis-image

Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis

Source from : PMLiVE - 4 days ago

Novo Nordisk and Echosens, a high-technology company specialising ... including type 2 diabetes โ€“ 44% of people with NASH live with type 2 diabetes. The diseaseโ€™s low diagnosis rate is linked to the ...See details»